News & Perspective

Jun 12, 2008

Jun 12, 2008

Baxter says cell-based H5N1 vaccine did well in trial

(CIDRAP News) – A pharmaceutical company is reporting good results in the first clinical trial of an H5N1 avian influenza vaccine that uses a whole, killed H5N1 virus grown in cell culture—a combination of techniques that entails some risk but may boost immune response and shorten production time.

Oct 17, 2006

Oct 17, 2006

Baxter says cell-based H5N1 vaccine shows potential in trial

(CIDRAP News) – Low doses of a cell-based avian flu vaccine triggered a good immune response to the H5N1 avian influenza virus, according to preliminary results of a clinical trial by Baxter International of Deerfield, Ill., maker of the vaccine.